College of Automation, Guangdong Polytechnic Normal University, Guangzhou, 510665, China.
Department of Surgery, Stanford University School of Medicine, Stanford, CA, 94305, USA.
BMC Pregnancy Childbirth. 2024 Nov 25;24(1):783. doi: 10.1186/s12884-024-06974-2.
Preterm birth (PTB) is a serious health problem. PTB complications is the main cause of death in infants under five years of age worldwide. The ability to accurately predict risk for PTB during early pregnancy would allow early monitoring and interventions to provide personalized care, and hence improve outcomes for the mother and infant.
This study aims to predict the risks of early preterm (< 35 weeks of gestation) or very early preterm (≤ 26 weeks of gestation) deliveries by using high-resolution maternal urinary metabolomic profiling in early pregnancy.
A retrospective cohort study was conducted by two independent preterm and term cohorts using high-density weekly urine sampling. Maternal urine was collected serially at gestational weeks 8 to 24. Global metabolomics approaches were used to profile urine samples with high-resolution mass spectrometry. The significant features associated with preterm outcomes were selected by Gini Importance. Metabolite biomarker identification was performed by liquid chromatography tandem mass spectrometry (LCMS-MS). XGBoost models were developed to predict early or very early preterm delivery risk.
The urine samples included 329 samples from 30 subjects at Stanford University, CA for model development, and 156 samples from 24 subjects at the University of Alabama, Birmingham, AL for validation.
12 metabolites associated with PTB were selected and identified for modelling among 7,913 metabolic features in serial-collected urine samples of pregnant women. The model to predict early PTB was developed using a set of 12 metabolites that resulted in the area under the receiver operating characteristic (AUROCs) of 0.995 (95% CI: [0.992, 0.995]) and 0.964 (95% CI: [0.937, 0.964]), and sensitivities of 100% and 97.4% during development and validation testing, respectively. Using the same metabolites, the very early PTB prediction model achieved AUROCs of 0.950 (95% CI: [0.878, 0.950]) and 0.830 (95% CI: [0.687, 0.826]), and sensitivities of 95.0% and 60.0% during development and validation, respectively.
Models for predicting risk of early or very early preterm deliveries were developed and tested using metabolic profiling during the 1st and 2nd trimesters of pregnancy. With patient validation studies, risk prediction models may be used to identify at-risk pregnancies prompting alterations in clinical care, and to gain biological insights of preterm birth.
早产(PTB)是一个严重的健康问题。PTB 并发症是全球 5 岁以下婴儿死亡的主要原因。在孕早期能够准确预测 PTB 的风险,将允许进行早期监测和干预,提供个性化的护理,从而改善母婴的结局。
本研究旨在通过在孕早期使用高分辨率母体尿液代谢组学分析,预测早期早产(<35 孕周)或极早期早产(≤26 孕周)的风险。
本研究通过两个独立的早产和足月队列进行回顾性队列研究,使用高密度的每周尿液采样。在妊娠 8 至 24 周时连续采集母体尿液。使用高分辨率质谱对尿液样本进行全局代谢组学分析。通过基尼重要性选择与早产结局相关的显著特征。通过液相色谱串联质谱(LCMS-MS)进行代谢物生物标志物鉴定。使用 XGBoost 模型预测早期或极早期早产的风险。
尿样包括来自加利福尼亚斯坦福大学的 30 名受试者的 329 个样本,用于模型开发,以及来自阿拉巴马伯明翰大学的 24 名受试者的 156 个样本,用于验证。
在对孕妇连续采集的尿液样本中的 7913 个代谢特征中,有 12 个代谢物与 PTB 相关,并被确定用于建模。用于预测早期 PTB 的模型使用一组 12 个代谢物,在开发和验证测试中,其受试者工作特征曲线下面积(AUROCs)分别为 0.995(95%CI:[0.992,0.995])和 0.964(95%CI:[0.937,0.964]),敏感性分别为 100%和 97.4%。使用相同的代谢物,极早期 PTB 预测模型的 AUROCs 分别为 0.950(95%CI:[0.878,0.950])和 0.830(95%CI:[0.687,0.826]),敏感性分别为 95.0%和 60.0%。
使用妊娠 1 至 2 期的代谢组学分析,开发和测试了预测早期或极早期早产风险的模型。通过患者验证研究,风险预测模型可用于识别高危妊娠,从而改变临床护理,并获得早产的生物学见解。